'Exenatide' presentation slideshows

Nuevos tratamientos en Diabetes mellitus tipo 2

642 views • 32 slides

NEW ORAL AGENTS IN DIABETES MANAGEMENT

NEW ORAL AGENTS IN DIABETES MANAGEMENT. DR WK SIGILAI Consultant physician,KNH. Mission and Vision. Our Vision To be a world class referral hospital in the provision of innovative and specialised healthcare Mission

290 views • 17 slides

Disclosure/Disclaimer

Disclosure/Disclaimer. All material is intended for your medical education purposes only. Effects Of Exenatide Versus Sitagliptin On Postprandial Glucose, Insulin and Glucagon Secretion, Gastric Emptying, And Caloric Intake: A Randomized, Cross-Over Study.

165 views • 15 slides

Featured Article :

Featured Article :. Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes.

302 views • 14 slides

GLP-1 Agonists and Cardiovascular Health

GLP-1 Agonists and Cardiovascular Health. Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM. Part 2 of 2. Change in Weight by Quartile at 82 Weeks. Change in A1C as a Function of Change in Weight at 82 Weeks.

182 views • 12 slides

New Diabetes Drugs DPP-4 Inhibitors Exenatide

New Diabetes Drugs DPP-4 Inhibitors Exenatide. Incretin effect. GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose Type 2 diabetics little incretin effect Reduced GLP-1 secretion GIP lost insulinotropic property GLP-1 broken down by DPP-4

323 views • 11 slides

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

Featured Article :. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Gayatri Sarkar, May Alattar, Rebecca J. Brown, Michael J. Quon, David M. Harlan, and Kristina I. Rother. Diabetes Care Volume 37: 666-670 March, 2014. STUDY OBJECTIVE.

231 views • 8 slides

AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c

AMYLIN PHARMACEUTICALS (AMLN) www.amylin.com Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market cap: 2.04 Bil Revenue: $13 Mil Expenses: ($119) Mil Net Loss: ($109) Mil P/E: N/A EPS: -1.51 Estimated target price: 27.3

534 views • 4 slides